WO2011070177A2 - Procédés destinés à faciliter la survie de cellules neuronales en utilisant des mimétiques de ligands de la famille des gdnf (gfl) ou des activateurs de la voie de signalisation du ret - Google Patents

Procédés destinés à faciliter la survie de cellules neuronales en utilisant des mimétiques de ligands de la famille des gdnf (gfl) ou des activateurs de la voie de signalisation du ret Download PDF

Info

Publication number
WO2011070177A2
WO2011070177A2 PCT/EP2010/069535 EP2010069535W WO2011070177A2 WO 2011070177 A2 WO2011070177 A2 WO 2011070177A2 EP 2010069535 W EP2010069535 W EP 2010069535W WO 2011070177 A2 WO2011070177 A2 WO 2011070177A2
Authority
WO
WIPO (PCT)
Prior art keywords
compound
ret
composition
alkyl
aryl
Prior art date
Application number
PCT/EP2010/069535
Other languages
English (en)
Other versions
WO2011070177A3 (fr
Inventor
Mart Saarma
Mati Karelson
Maxim Bespalov
Mehis Pilv
Original Assignee
Baltic Technology Development, Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baltic Technology Development, Ltd. filed Critical Baltic Technology Development, Ltd.
Priority to JP2012542580A priority Critical patent/JP2013513588A/ja
Priority to CN2010800637467A priority patent/CN103180297A/zh
Priority to CA2783934A priority patent/CA2783934A1/fr
Priority to BR112012014022A priority patent/BR112012014022A2/pt
Priority to EP10790954.1A priority patent/EP2509953B1/fr
Priority to MX2012006580A priority patent/MX2012006580A/es
Priority to AU2010329847A priority patent/AU2010329847A1/en
Priority to US13/514,906 priority patent/US8901129B2/en
Publication of WO2011070177A2 publication Critical patent/WO2011070177A2/fr
Publication of WO2011070177A3 publication Critical patent/WO2011070177A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C07D215/46—Nitrogen atoms attached in position 4 with hydrocarbon radicals, substituted by nitrogen atoms, attached to said nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D219/00—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems
    • C07D219/04—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • C07D219/08—Nitrogen atoms
    • C07D219/10—Nitrogen atoms attached in position 9
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D263/57—Aryl or substituted aryl radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C07D285/135—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/192—Radicals derived from carboxylic acids from aromatic carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/10—Spiro-condensed systems

Definitions

  • the "stay alive” signals are usually carried by neurotrophic factors promoting neuronal survival.
  • neurotrophic factors promoting neuronal survival.
  • pathological conditions such as Parkinson's (PD) and Alzheimer's diseases, neurons progressively degenerate. Neurons loose synaptic contacts, undergo axonal degeneration, and eventually die.
  • Glial cell line-derived neurotrophic factor is a distant member of the transforming growth factor ⁇ superfamily and a founding member of the GDNF family ligands (GFL).
  • GFL GDNF family ligands
  • This family consists of four members: GDNF, neurturin (NRTN), artemin (ARTN) and persephin (PSPN) (Fig. 1), all of which are potent neurotrophic factors (Airaksinen and Saarma, 2002). Since its discovery in 1993, GDNF has attracted substantial attention for its ability to support the survival of dopaminergic neurons, induce axonal sprouting and regulate functional dopamine metabolism in these neurons, which degenerate in PD (Lin et al., 1993). In addition, GDNF is one of the few growth factors that not only protects, but also repairs dopamine neurons in animal models of PD
  • GDNF has already shown protective and neurorestorative effects in a number of animal models of Parkinson's disease and demonstrated very promising results in two clinical trials (Gill et al., 2003; Slevin et al., 2005), a recent study failed to show clear clinical benefits of GDNF (Lang et al., 2006). This discrepancy might be explained by differences in trial setups, disease state of the patients and the properties of E. coli expressed GDNF. To date, there is no clear understanding why these three trials resulted in different outcomes.
  • GDNF may also be important for the treatment of amyotrophic lateral sclerosis (ALS) as GDNF is supportive for motoneurons (Henderson et al., 1994).
  • ALS amyotrophic lateral sclerosis
  • GDNF or its mimetics could also be used as male contraceptives (Meng et al., 2000).
  • NRTN is a very promising molecule as recent Phase II clinical trials with intraputamenal injections of adenovirus bearing NRTN gene demonstrated a significant improvement in Parkinson's disease patients (Ceregene Inc., press release).
  • ARTN is being tested for neuropathy in Phase I trials conducted by Biogen Idec/NsGene as it was demonstrated to be efficient in animal model of chronic pain (Gardell et al., 2003) and being restorative for sensory neurons (Wang et al., 2008).
  • PSPN is considered for the treatment of stroke and Alzheimer's disease (Golden et al., 2003; Tomac et al., 2002)
  • GFLs-receptor complex While the GFLs-receptor complex is considered as an adequate drug target, the GFLs polypeptides are probably the inappropriate pharmacological agents.
  • One hurdle in protein-based therapies is bioavailability.
  • GDNF is a basic protein of 134 amino acids, which is unable to penetrate the blood-brain barrier. Therefore, brain surgery is required to deliver it.
  • GDNF, NRTN and ARTN interact with heparan sulfates - the components of the extracellular matrix (ECM) (Lin et al., 1993). This interaction dramatically reduces the diffusion of GFLs from the area of its application or production.
  • ECM extracellular matrix
  • Recombinant GDNF may induce inflammation and formation of anti-GDNF antibodies (Lang et al., 2006) and the price of recombinant GDNF is high.
  • the properties of E. coli- produced recombinant GDNF may vary from batch to batch, since it is first produced as an inactive protein followed by in vitro renaturation.
  • GDNF is promiscuous; not only can it activate RET through GFRal (weakly also through GFRa2 and GFRa3), but GDNF can also activate completely different receptors: neural cell adhesion molecule NCAM and syndecan glycoproteins that carry GDNF-binding heparan sulphate side chains (Bespalov et al., unpublished) (Sariola and Saarma, 2003). These pleiotropic GDNF actions can lead to multiple side-effects.
  • small molecules do not trigger permanent RET activation, since they are delivered at defined time intervals and they are rapidly degraded in the organism.
  • the risk of carcinogenesis is further reduced by the fact that GDNF- mimetics are partial agonists.
  • the present invention is related to a method of treating a disorder that can be treated by contacting, activating or inhibiting a GFR /RET receptor complex in a subject in need of treatment thereof, comprising administering to the subject an effective amount of a compound having binding and/or modulation specificity for a GFRal receptor molecule, thereby treating the disorder.
  • compositions comprising one or more of these compounds and a pharmaceutically acceptable diluent, excipient, or carrier, are an aspect of the invention.
  • unit dose formulations of one or more of the compounds are an aspect of the invention.
  • a medical device such as a syringe that contains the compound or composition is an aspect of the invention.
  • the disorders targeted by the present invention include Alzheimer's disease, Huntington's disease, amyotrophic lateral sclerosis, Rett syndrome, epilepsy, Parkinson's disease, spinal cord injury, stroke, hypoxia, ischemia, brain injury, diabetic neuropathy, peripheral neuropathy, nerve transplantation complications, motor neuron disease, multiple sclerosis, HIV dementia, peripheral nerve injury, hearing loss, depression, obesity, metabolic syndrome, pain, cancer, and other conditions involving degeneration or dysfunction of cells expressing GFR /RET.
  • the selecting of a human subject shall be construed to be restricted to selecting based on testing of a biological sample that has previously been removed from a human body and/or based on information obtained from a medical history, patient interview, or other activity that is not practiced on the human body; and (2) the administering of a composition to a human subject shall be restricted to prescribing a controlled substance that a human subject will self-administer by any technique (e.g., orally, inhalation, topical application, injection, insertion, etc.); or that a person other than the prescribing authority shall administer to the subject.
  • any technique e.g., orally, inhalation, topical application, injection, insertion, etc.
  • the invention includes, as an additional aspect, all embodiments of the invention narrower in scope in any way than the variations specifically mentioned above.
  • aspects of the invention may have been described by reference to a genus or a range of values for brevity, it should be understood that each member of the genus and each value or sub-range within the range is intended as an aspect of the invention.
  • various aspects and features of the invention can be combined, creating additional aspects which are intended to be within the scope of the invention.
  • FIG. 1 GDNF family ligands (GFLs) and their receptors. GFLs can not bind the signal-transducing receptor RET directly but require glycosylphosphatidylinositol (GPI)-anchored GFRa. GDNF, neurturin (NRTN), artemin (ARTN) and persephin (PSPN) can all interact with and signal through GFR /RET receptor complexes. TM - transmembrane domain. All proteins are represented as solid ribbons.
  • Figure 2 Validation of GFLs-signaling-mimetics using proprietary cell-based luciferase-reporter system. Structures of several compounds screened are as follows:
  • compound 243G7 has a structure of Formula (VIII), described below;
  • compound 299B5 has a structure of formula (X), described below;
  • compound 290A11 has a structure of:
  • compound 375F4 has a structure of
  • Compound 219902 has a structure of
  • compound 74609 has a structure of
  • FIG. 4 Selected GFL-mimetics can potently activate RET via GFRcc as revealed by phosphorylation assay.
  • WB Western blotting.
  • IP immunoprecipitation.
  • pY aniti-phospho-tyrosine antibodies.
  • the asterisk indicates GLF-mimetic compounds that induce RET activation.
  • the lane numbers and compounds were as follows: 1) dimethyl sulfoxide (DMSO); 2) inactive compound chloroquine having a structure
  • Figure 5 shows the dose-response for the compounds applied to the GFRal/RET- expressing cells (upper panel), GFRa3/RET- or RET-expressing reporter cell lines (lower panel).
  • the signaling cascade activated by GFRo/RET leads to the activation of MAPK, which leads to induction of the luciferase reporter.
  • the compounds BT13, BT16, BT17 and can in a dose-dependent manner induce luciferase expression in GFRal/RET and in GFRa3/RET-expressing reporter cell lines. No significant effect was observed in cells expressing RET alone.
  • Compound BT18 was active in GFRal/RET-cell line.
  • the structure for BT10 is ; the structure for BT13 (alternatively called herein N13) is is
  • BT16 (alternatively called herein N the structure for BT17 (alternatively called herein N17) is
  • Figure 6 shows RET phosphorylation induced by novel (BT) GDNF-/ARTN mimetics, The structu 19 are as shown for Figure 5; and the
  • FIG. 6A shows activation of GFRal/RET by various BT compounds, the structures for which are shown above: MG87 RET fibroblasts were transfected with GFRal construct and treated with a BT test compound at 100 ⁇ concentration.
  • the upper panel represents the membrane containing the immunoprecipitated with RET antibodies (IP: RET) lysed that were probed with anti-phosphotyosine antibodies (WB: pY).
  • FIG. 6B shows Activation of GFRa3/RET by BT compounds.
  • MG87 RET fibroblasts were transfected with either GFRa3 or GFP constructs and treated with BT compounds, the structures of which are shown above, at 100 ⁇ concentration.
  • the upper panel represents the membrane containing the immunoprecipitated with RET antibodies (IP: anti-RET) lysed that were probed with anti-phosphotyrosine antibodies (WB: pY).
  • Compound BT13 strongly activated RET via GFRa3.
  • Compounds BT16, BT17 and BT18 are likely the weaker GFRa3/RET agonists.
  • the lower panel shows the same membrane probed with anti-RET antibodies (WB: anti-RET).
  • Thirty microliters (30 ⁇ ) of DMSO were used as a negative control in GFRa3-transfected cells.
  • ARTN 100 ng/ml
  • Figure 7 shows effect of intrastriatal injection of vehicle, GDNF (10 ⁇ g) or GDNF mimetics at indicated concentrations (0.2-5 ⁇ g) on amphetamine-induced rotation.
  • Rats received vehicle, GDNF or BT GDNF mimetics compounds, the structures of which are shown above, in the striatum three weeks after the lesion was induced by intrastriatal 6- OHDA (28 micrograms). Amphetamine-induced behavior was measured 6 weeks post lesion.
  • Figure 8 shows the cell growth of murine fibroblasts in the presence of the indicated BT compounds.
  • the structures of BT10, 13, 16, 17, 18, and 19 are as shown above.
  • the results are represented as percentage of living cells from DMSO control (which is assumed as viability of 100+5 percent). All compounds showed moderate cell growth inhibition at 50 ⁇ concentration (except for BT10 that has showed significant toxicity at concentrations above 2 ⁇ ).
  • Figure 9 shows the effect of intrastriatal injection of vehicle or GDNF (10 ⁇ g) or a GDNF mimetic (dose indicated) on amphetamine-induced rotation. Structures of the compounds are as indicated above.
  • GDNF mimetic compounds binding and/or modulation specificity for a GFRa receptor molecules
  • RET signaling activating compounds downstream RET signaling
  • the compound is administered in a composition that also includes one or more pharmaceutically acceptable diluents, adjuvants, or carriers.
  • treating is considered a success if any of the following therapeutic goals are achieved: symptoms of the disease are ameliorated, alleviated, or diminished; progression of the disease or disease symptoms is slowed or arrested; deterioration or injury is alleviated, partially healed, or fully healed; and/or if the subject makes a partial or complete recovery; and/or other standard-of-care therapies that are more expensive, more difficult to administer, or have less acceptable side-effects can be reduced or eliminated while achieving a similar quality of life.
  • the disorder can be, for example, Alzheimer's disease, Huntington's disease, amyotrophic lateral sclerosis, Rett syndrome, epilepsy, Parkinson's disease, spinal cord injury, stroke, hypoxia, ischemia, brain injury, diabetic neuropathy, peripheral neuropathy, nerve transplantation complications, motor neuron disease, multiple sclerosis, HIV dementia, peripheral nerve injury, hearing loss, depression, obesity, metabolic syndrome, pain, cancer, or conditions involving degeneration or dysfunction of cells expressing GFRa and/or RET.
  • Alzheimer's disease Huntington's disease, amyotrophic lateral sclerosis, Rett syndrome, epilepsy, Parkinson's disease, spinal cord injury, stroke, hypoxia, ischemia, brain injury, diabetic neuropathy, peripheral neuropathy, nerve transplantation complications, motor neuron disease, multiple sclerosis, HIV dementia, peripheral nerve injury, hearing loss, depression, obesity, metabolic syndrome, pain, cancer, or conditions involving degeneration or dysfunction of cells expressing GFRa and/or RET.
  • the subject can be an animal or a human subject.
  • the animal can be a mammal.
  • the compound can be a small molecule.
  • GDNF mimetic compound has a structure of Formula (I),
  • Rl and R2 are independently selected from the group consisting of H, alkyl, aryl, alkylenearyl, acyl, alkoxycarbonyl, aryloxycarbonyl, alkylenearyloxycarbonyl, carbamoyl, alkylcarbamoyl, dialkylcarbamoyl, and alkyleneamino;
  • R3 is independently selected from H, fluorine, chlorine, bromine, iodide, alkyl, aryl, alkylenearyl, acyl, alkoxycarbonyl, ⁇ aryloxycarbonyl, alkylenearyloxycarbonyl, carbamoyl, alkylcarbamoyl, and dialkyl- carbamoyl and
  • R4 is selected from the group consisting of H, alkyl, aryl, alkylenearyl, alkenylenearyl, hydroxyl; or a pharmaceutically acceptable salt thereof.
  • Rl and R2 are independently selected from the group consisting of alkyleneamino and hydrogen, where the amino group of the alkyleneamino moiety can be further substituted with one or two alkyl or alkylenearyl (e.g., a benzyl) groups.
  • R3 is chloro or aminoalkyl.
  • Rl is hydrogen and R2 is alkyleneamino.
  • the GDNF mimetic compound has a structure of Formula (II)
  • Rl and R2 are independently selected from the group consisting of H, alkyl, aryl, alkylenearyl, acyl, alkoxycarbonyl, aryloxycarbonyl, alkylenearyloxycarbonyl, carbamoyl, alkylcarbamoyl, dialkylcarbamoyl, and alkyleneamino;
  • R3, R4, R5, and R6 are independently selected from the group consisting of H, alkyl, aryl, alkylenearyl, acyl, alkoxycarbonyl, aryloxycarbonyl, alkylenearyloxycarbonyl, carbamoyl, alkylcarbamoyl, dialkylcarbamoyl, and alkyleneamino;
  • R3, R4, R5, and R6 are independently selected from the group consisting of H, alkyl, aryl, alkylenearyl, acyl, alkoxycarbonyl, aryloxycarbonyl, alkylenearyloxycarbon
  • alkylenearyl acyl, alkoxycarbonyl, aryloxycarbonyl, alkylenearyloxycarbonyl, carbamoyl, alkylcarbamoyl, and dialkylcarbamoyl; or a pharmaceutically acceptable salt thereof.
  • the GDNF mimetic compound has a structure of Formula (III)
  • Rl and R2 are independently selected from the group consisting of H, alkyl, aryl, alkylenearyl, acyl, alkoxycarbonyl, aryloxycarbonyl, alkylenearyloxycarbonyl, carbamoyl, alkylcarbamoyl, dialkylcarbamoyl, and alkyleneamino;
  • R3, R4, R5, and R6 are independently selected from the group consisting of H, alkyl, aryl, alkylenearyl, acyl, alkoxycarbonyl, aryloxycarbonyl, alkylenearyloxycarbonyl, carbamoyl, alkylcarbamoyl, dialkylcarbamoyl, and alkyleneamino;
  • R3, R4, R5, and R6 are independently selected from the group consisting of H, alkyl, aryl, alkylenearyl, acyl, alkoxycarbonyl, aryloxycarbonyl, alkylenearyloxycarbon
  • the GDNF mimetic compound has a structure of Formula (IV)
  • Rl and R2 are independently selected from the group consisting of H, alkyl, aryl, alkylenearyl, acyl, alkoxycarbonyl, aryloxycarbonyl, alkylenearyloxycarbonyl, carbamoyl, alkylcarbamoyl, dialkylcarbamoyl, alkyleneamino;
  • R3, R4, R5, and R6 are independently selected from H, fluorine, chlorine, bromine, iodide, alkyl, aryl, alkylenearyl, acyl, alkoxycarbonyl, aryloxycarbonyl, alkylenearyloxycarbonyl, carbamoyl, alkylcarbamoyl, and dialkylcarbamoyl; or a pharmaceutically acceptable salt thereof.
  • the RET signaling activating compound has a structure of Formula (V)
  • Rl and R2 are independently selected from the group consisting of H, alkyl, aryl, alkylenearyl, acyl, alkoxycarbonyl, aryloxycarbonyl, alkylenearyloxycarbonyl, carbamoyl, alkylcarbamoyl, dialkylcarbamoyl, alkyleneamino;
  • R3 is independently selected from H, fluorine, chlorine, bromine, iodide, alkyl, aryl, alkylenearyl, acyl, alkoxy, alkoxycarbonyl, aryloxycarbonyl, alkylenearyloxycarbonyl, carbamoyl, alkylcarbamoyl, and
  • dialkylcarbamoyl or a pharmaceutically acceptable salt thereof.
  • the RET signaling activating compound has a structure of Formula (VI)
  • RET signaling activating compound has a structure of Formula (VII)
  • the RET signaling activating compound has a structure of Formula (VIII)
  • the RET signaling activating compound has a structure of Formula (IX) or a pharmaceutically acceptable salt thereof.
  • the RET signaling activating compound has a structure of Formula (X)
  • the RET signaling activating compound has a structure of Formula (XI)
  • the RET signaling activating compound has a structure of Formula (XII)
  • the RET signaling activating compound has a structure of Formula (XIII)
  • the RET signaling activating compound has a structure of any one of the following formulae
  • the RET signaling activating compound has a structure of Formula (XX):
  • Rl is a cyclic or acyclic amino group, or a pharmaceutically acceptable salt thereof.
  • Rl groups include dialkyl amino, piperidinyl, substituted piperidinyl, piperazinyl; substituted piperazinyl; tetrahydroisoquinolinyl; and substituted tetrahydroisoquinolinyl.
  • alkyl refers to straight chained and branched hydrocarbon groups containing carbon atoms, typically methyl, ethyl, and straight chain and branched propyl and butyl groups. Unless otherwise indicated, the hydrocarbon group can contain up to 20 carbon atoms.
  • the term “alkyl” includes "bridged alkyl,” i.e., a C 6 - C 16 bicyclic or polycyclic hydrocarbon group, for example, norbornyl, adamantyl, bicyclo[2.2.2]octyl, bicyclo[2.2.1]heptyl, bicyclo[3.2.1]octyl, or decahydronaphthyl.
  • Alkyl groups optionally can be substituted, for example, with hydroxy (OH), halo, amino, and sulfonyl.
  • An "alkoxy” group is an alkyl group having an oxygen substituent, e.g., -O- alkyl.
  • alkenyl refers to straight chained and branched hydrocarbon groups containing carbon atoms having at least one carbon-carbon double bond. Unless otherwise indicated, the hydrocarbon group can contain up to 20 carbon atoms. Alkenyl groups can optionally be substituted, for example, with hydroxy (OH), halo, amino, and sulfonyl.
  • alkylene refers to an alkyl group having a further defined substituent.
  • alkylenearyl refers to an alkyl group substituted with an aryl group
  • alkyleneamino refers to an alkyl groups substituted with an amino group.
  • the amino group of the alkyleneamino can be further substituted with, e.g., an alkyl group, an alkylenearyl group, an aryl group, or combinations thereof.
  • alkenylene refers to an alkenyl group having a further defined substituent.
  • aryl refers to a monocyclic or polycyclic aromatic group, preferably a monocyclic or bicyclic aromatic group, e.g., phenyl or naphthyl.
  • an aryl group can be unsubstituted or substituted with one or more, and in particular one to four groups independently selected from, for example, halo, alkyl, alkenyl, OCF 3 , N0 2 , CN, NC, OH, alkoxy, amino, C0 2 H, C0 2 alkyl, aryl, and heteroaryl.
  • exemplary aryl groups include, but are not limited to, phenyl, naphthyl, tetrahydronaphthyl, chlorophenyl, methylphenyl, methoxyphenyl, trifluoromethylphenyl, nitrophenyl, 2,4-methoxychlorophenyl, and the like.
  • An "aryloxy" group is an aryl group having an oxygen substituent, e.g., -O-aryl.
  • acyl refers to a carbonyl group, e.g., C(O).
  • the acyl group is further substituted with, for example, hydrogen, an alkyl, an alkenyl, an aryl, an alkenylaryl, an alkoxy, or an amino group.
  • Specific examples of acyl groups include, but are not limited to, alkoxycarbonyl (e.g., C(O)-Oalkyl); aryloxycarbonyl (e.g., C(O)-Oaryl); alkylenearyloxycarbonyl (e.g., C(O)-Oalkylenearyl); carbamoyl (e.g., C(0)-NH 2 );
  • alkylcarbamoyl e.g., C(0)-NH(alkyl)
  • dialkylcarbamoyl e.g., C(0)-NH(alkyl) 2
  • amino refers to a nitrogen containing substituent, which can have zero, one, or two alkyl, alkenyl, aryl, alkylenearyl, or acyl substituents.
  • An amino group having zero substituents is -NH 2 .
  • halo or halogen refers to fluoride, bromide, iodide, or chloride.
  • the term "pharmaceutically acceptable salt” refers to those salts which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response and the like, and are commensurate with a reasonable benefit/risk ratio.
  • Pharmaceutically acceptable salts are well known in the art. For example, S. M. Berge, et al. describes pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences, 66: 1-19 (1977).
  • the salts can be prepared in situ during the final isolation and purification of the compounds of the invention, or separately by reacting the free base function with a suitable organic acid or inorganic acid.
  • nontoxic acid addition salts include, but are not limited to, salts of an amino group formed with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid or with organic acids such as acetic acid, maleic acid, tartaric acid, citric acid, succinic acid lactobionic acid or malonic acid or by using other methods used in the art such as ion exchange.
  • inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid
  • organic acids such as acetic acid, maleic acid, tartaric acid, citric acid, succinic acid lactobionic acid or malonic acid or by using other methods used in the art such as ion exchange.
  • salts include, but are not limited to, adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2-hydroxy- ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pam
  • alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, and the like.
  • Further pharmaceutically acceptable salts include, when appropriate, nontoxic ammonium, quaternary ammonium, and amine cations formed using counterions such as halide, hydroxide, carboxylate, sulfate, phosphate, nitrate, alkyl having from 1 to 6 carbon atoms, sulfonate and aryl sulfonate.
  • the compounds disclosed herein can also be admixed, encapsulated, conjugated or otherwise associated with other molecules, molecule structures or mixtures of compounds, as for example, liposomes, carriers, diluents, receptor-targeted molecules, oral, rectal, topical or other formulations, for assisting in uptake, distribution and/or absorption.
  • compositions and formulations which include the compounds described.
  • the pharmaceutical compositions can be administered in a number of ways depending upon whether local or systemic treatment is desired and upon the area to be treated. Administration may be topical (including ophthalmic and to mucous membranes including vaginal and rectal delivery), pulmonary, e.g., by inhalation or insufflation of powders or aerosols, including by nebulizer;
  • Parenteral administration includes intravenous, intraarterial, subcutaneous, intraperitoneal or intramuscular injection or infusion; or intracranial, e.g., intrathecal or intraventricular, administration.
  • Pharmaceutical compositions and formulations for topical administration may include transdermal patches, ointments, lotions, creams, gels, drops, suppositories, sprays, liquids and powders. Conventional pharmaceutical carriers, aqueous, powder or oily bases, thickeners and the like may be necessary or desirable.
  • the pharmaceutical formulations which may conveniently be presented in unit dosage form, can be prepared according to conventional techniques well known in the pharmaceutical industry. Such techniques include the step of bringing into association the active ingredients with the pharmaceutical carrier(s) or excipient(s). In general, the formulations are prepared by uniformly and intimately bringing into association the active ingredients with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product.
  • compositions can be formulated into any of many possible dosage forms such as, but not limited to, tablets, capsules, gel capsules, liquid syrups, soft gels, suppositories, and enemas.
  • the compositions can also be formulated as suspensions in aqueous, non-aqueous or mixed media.
  • Aqueous suspensions can further contain substances which increase the viscosity of the suspension including, for example, sodium carboxymethylcellulose, sorbitol and/or dextran.
  • the suspension may also contain stabilizers.
  • compositions include, but are not limited to, solutions, emulsions, foams and liposome-containing formulations.
  • the pharmaceutical include, but are not limited to, solutions, emulsions, foams and liposome-containing formulations.
  • compositions and formulations of the present invention may comprise one or more penetration enhancers, carriers, excipients, diluents, or other active or inactive ingredients.
  • Emulsions are typically heterogeneous systems of one liquid dispersed in another in the form of droplets usually exceeding 0.1 ⁇ in diameter. Emulsions can contain additional components in addition to the dispersed phases, and the active drug which is present as a solution in either the aqueous phase, oily phase, or itself as a separate phase. Microemulsions are included as an embodiment of the disclosure. Emulsions and their uses are well known in the art and are further described in U.S. Patent 6,287,860, which is incorporated herein in its entirety.
  • Formulations can include liposomal formulations.
  • liposome means a vesicle composed of amphiphilic lipids arranged in a spherical bilayer or bilayers. Liposomes are unilamellar or multilamellar vesicles which have a membrane formed from a lipophilic material and an aqueous interior that contains the composition to be delivered. Liposomes also include "sterically stabilized" liposomes, a term which, as used herein, refers to liposomes comprising one or more specialized lipids that, when incorporated into liposomes, result in enhanced circulation lifetimes relative to liposomes lacking such specialized lipids.
  • sterically stabilized liposomes are those in which part of the vesicle-forming lipid portion of the liposome comprises one or more glycolipids or is derivatized with one or more hydrophilic polymers, such as a polyethylene glycol (PEG) moiety.
  • PEG polyethylene glycol
  • Liposomes and their uses are further described in U.S. Patent 6,287,860, which is incorporated herein in its entirety.
  • the pharmaceutical formulations and compositions disclosed herein can also include surfactants. The use of surfactants in drug products, formulations and in emulsions is well known in the art. Surfactants and their uses are further described in U.S. Patent 6,287,860, which is incorporated herein in its entirety.
  • formulations comprising one or more penetration enhancers to effect the efficient delivery of the compounds disclosed herein.
  • penetration enhancers also enhance the permeability of lipophilic drugs.
  • Penetration enhancers can be classified as belonging to one of five broad categories, i.e., surfactants, fatty acids, bile salts, chelating agents, and non-chelating non- surfactants. Penetration enhancers and their uses are further described in U.S. Patent 6,287,860, which is incorporated herein in its entirety.
  • formulations are routinely designed according to their intended use, i.e. route of administration.
  • Preferred formulations for topical administration include those in which the compounds of the invention are in admixture with a topical delivery agent such as lipids, liposomes, fatty acids, fatty acid esters, steroids, chelating agents and surfactants.
  • a topical delivery agent such as lipids, liposomes, fatty acids, fatty acid esters, steroids, chelating agents and surfactants.
  • Preferred lipids and liposomes include neutral (e.g. dioleoylphosphatidyl DOPE
  • ethanolamine dimyristoylphosphatidyl choline DMPC, distearolyphosphatidyl choline) negative (e.g. dimyristoylphosphatidyl glycerol DMPG) and cationic (e.g.
  • compositions and formulations for oral administration include powders or granules, microparticulates, nanoparticulates, suspensions or solutions in water or non- aqueous media, capsules, gel capsules, sachets, tablets or minitablets. Thickeners, flavoring agents, diluents, emulsifiers, dispersing aids or binders may be desirable.
  • Preferred oral formulations are those in which compounds are administered in conjunction with one or more penetration enhancers surfactants and chelators.
  • Preferred surfactants include fatty acids and/or esters or salts thereof, bile acids and/or salts thereof.
  • Preferred bile acids/salts and fatty acids and their uses are further described in U.S. Patent 6,287,860, which is incorporated herein in its entirety.
  • Also preferred are combinations of penetration enhancers, for example, fatty acids/salts in combination with bile acids/salts.
  • More preferred combination is the sodium salt of lauric acid, capric acid and UDCA.
  • Further penetration enhancers include polyoxyethylene-9-lauryl ether, polyoxyethylene- 20-cetyl ether.
  • Compounds of the invention may be delivered orally, in granular form including sprayed dried particles, or complexed to form micro or nanoparticles.
  • compositions and formulations for parenteral, intrathecal or intraventricular administration can include sterile aqueous solutions which can also contain buffers, diluents and other suitable additives such as, but not limited to, penetration enhancers, carrier compounds and other pharmaceutically acceptable carriers or excipients.
  • the active compounds can be administered by using various now strategies for gaining drug access to the brain.
  • Various strategies known in the art for increasing transport across the BBB can be adapted to the compounds of the invention to thereby enhance transport of the modulators across the BBB (for reviews of such strategies, see e.g., Pardridge. Trends in Biotechnol. 12:239-245 (1994); Van Bree, et al. Pharm. World Sci. 15:2-9 (1993); and Pardridge, et al. Pharmacol. Toxicol. 71:3-10 (1992)).
  • the compound is chemically modified to form a prodrug with enhanced transmembrane transport. Suitable chemical modifications include covalent linking of a fatty acid to the compound through an amide or ester linkage (see e.g., U.S. Pat. No.
  • N-acylamino acid derivatives may be used in a modulator to form a "lipidic" prodrug (see e.g., U.S. Pat. No. 5,112,863).
  • a peptidic or peptidomimetic compound is conjugated to a second peptide or protein, thereby forming a chimeric protein, wherein the second peptide or protein undergoes absorptive-mediated or receptor-mediated transcytosis through the BBB. Accordingly, by coupling a compound as disclosed herein to this second peptide or protein, the chimeric protein is transported across the BBB.
  • the second peptide or protein can be a ligand for a brain capillary endothelial cell receptor ligand.
  • a preferred ligand is a monoclonal antibody that specifically binds to the transferrin receptor on brain capillary endothelial cells (see e.g., U.S. Pat. Nos. 5,182,107 and 5,154,924 and PCT Publications WO 93/10819 and WO 95/02421).
  • Other suitable peptides or proteins that can mediate transport across the BBB include histones (see e.g., U.S. Pat. No. 4,902,505) and ligands such as biotin, folate, niacin, pantothenic acid, riboflavin, thiamin, pryridoxal and ascorbic acid (see e.g., U.S. Pat. Nos. 5,416,016 and 5,108,921).
  • the glucose transporter GLUT-1 has been reported to transport glycopeptides (L-serinyl-P-D-glucoside analogues of
  • a compound can be coupled to such a glycopeptide to target the modulator to the GLUT-1 glucose transporter.
  • a compound which is modified at a free amine with the modifying group Aic 3-(0-aminoethyl-iso)-cholyl, a derivative of cholic acid having a free amino group
  • Aic 3-(0-aminoethyl-iso)-cholyl, a derivative of cholic acid having a free amino group
  • Chimeric proteins can be formed by recombinant DNA methods (e.g., by formation of a chimeric gene encoding a fusion protein) or by chemical crosslinking of the modulator to the second peptide or protein to form a chimeric protein.
  • Numerous chemical crosslinking agents are known in the art (e.g., commercially available from Pierce, Rockford ⁇ 1.).
  • a crosslinking agent can be chosen which allows for high yield coupling of the modulator to the second peptide or protein and for subsequent cleavage of the linker to release bioactive modulator.
  • a biotin-avidin-based linker system may be used.
  • the compound is encapsulated in a carrier vector which mediates transport across the BBB.
  • the compound can be encapsulated in a liposome, such as a positively charged unilamellar liposome (see e.g., PCT Publications WO 88/07851 and WO 88/07852) or in polymeric microspheres (see e.g., U.S. Pat. No. 5,413,797; U.S. Pat. No. 5,271,961; and U.S. Pat. No. 5,019,400).
  • the carrier vector can be modified to target it for transport across the BBB.
  • the carrier vector e.g., liposome
  • the carrier vector can be covalently modified with a molecule which is actively transported across the BBB or with a ligand for brain endothelial cell receptors, such as a monoclonal antibody that specifically binds to transferrin receptors (see e.g., PCT Publications WO 91/04014 and WO 94/02178).
  • the compound in still another approach to enhancing transport of the modulator across the BBB, can be coadministered with another agent which functions to permeabilize the BBB.
  • BBB "permeabilizers” include bradykinin and bradykinin agonists (see e.g., U.S. Pat. No. 5,112,596) and peptidic compounds disclosed in U.S. Pat. No. 5,268,164.
  • Dosing is determined, e.g., by dose-response, toxicity, and pharmacokinetic studies. Dosing is dependent on severity and responsiveness of the disease state to be treated, with the course of treatment lasting from several days to several months, or until a cure is effected, or a diminution of the disease state or disease symptoms is achieved. Dosing may continue indefinitely for chronic disease states or conditions for which diminution but no cure can be achieved. Optimal dosing schedules can be calculated from measurements of drug accumulation in the body of the patient. Persons of ordinary skill can easily determine optimum dosages, dosing methodologies and repetition rates.
  • Optimum dosages may vary depending on the relative potency of individual oligonucleotides, and can generally be estimated based on EC 50 S found to be effective in in vitro and in vivo animal models. In general, dosage is from 0.01 ⁇ g to 100 g per kg of body weight, and may be given once or more daily, weekly, monthly or yearly, or even once every 2 to 20 years. Persons of ordinary skill in the art can easily estimate repetition rates for dosing based on measured residence times and concentrations of the drug in bodily fluids or tissues.
  • oligonucleotide is administered in maintenance doses, ranging from 0.01 ⁇ g to 100 g per kg of body weight, once or more daily, to once every 20 years.
  • the assay can provide high throughput analyses of compounds. For example, cells expressing GFR l are contacted with a compound of interest and an increase in cell growth indicates whether the compound is a GDNF mimetic, where cell growth of the mimetic assay is compared to a background control experiment with no compound.
  • the cells are cells that express luciferase as well as GFRal, and the indicator of cell growth is luciferase. Measurement of cell growth can be by measuring
  • compounds are selected that are specific for a single receptor selected from the group consisting of GFRal, GFRa2, GFRa3, and GFRa4. In other cases, compounds are selected that modulate two, three, or all four of these receptors.
  • the assays of the invention also can be practiced using a positive control, e.g., a natural ligand for the receptor(s) of interest.
  • a positive control e.g., a natural ligand for the receptor(s) of interest.
  • receptor binding compounds can be selected that inhibit ligand-mediated activation of GFRal, GFRa2, GFRa3, and/or GFRa4.
  • Preferred ligand receptor combinations are depicted in Figure 1. This figure also depicts exemplary disease indications for compounds that mimic or modulate or interfere with specific ligand/receptor interactions.
  • Another method disclosed herein comprises a double antibody sandwich ELISA assay to evaluate a compound as a GDNF mimetic, which in some embodiments, can provide quantitative measurement of the mimetic' s activity.
  • Cells expressing RET and GFRal are contacted with a compound of interest, then contacted first with an anti-RET antibody then with an anti-pY antibody, such as a mouse anti-pY antibody, to form a double antibody sandwich, where formation of the double antibody sandwich indicates the compound as a GDNF mimetic.
  • detection of the sandwich can be by indirect detection, such as, when the anti-pY antibody is a mouse antibody, contacting the sandwich with a secondary anti-mouse HRP- conjugated antibody and a chemiluminescent reagent, such as ECL reagent, and measuring the resulting luminescence.
  • indirect detection such as, when the anti-pY antibody is a mouse antibody, contacting the sandwich with a secondary anti-mouse HRP- conjugated antibody and a chemiluminescent reagent, such as ECL reagent, and measuring the resulting luminescence.
  • GDNF ARTN
  • NGF was purchased from Promega. Concentration of all GFLs was checked by microBCA kit (Pierce) using BSA as a standard.
  • the MAPK activation detection system (Baloh et al., 2000) and PathDetect Elk-1 (Stratagene) both of which include two plasmids.
  • the other plasmid, Gal4-Luc carries luciferase gene under the control of a synthetic promoter containing the yeast GAL4 binding sequences.
  • MG87RET murine fibroblast were plated on 35 mM dishes and transfected with 4 ⁇ g of G4-Luc, Gal4-Elk (Baloh et al., 2000) and GFRal expressing plasmid ("aLUC” cells) or empty vector ("NOa” cells) containing neomycin- resistance gene in ratio 4: 1: 1 using Lipofectamine 2000 (Invitrogen) for DNA delivery as described by manufacturer. The following day, cells were trypsinized and plated in low density on 10-cm tissue culture dishes. Stable transformants were selected in the presence of 500- 750 ⁇ g/ml geneticin (Invitrogen).
  • Established cell lines were maintained in DMEM, 10% fetal bovine serum (FBS), 100 ⁇ g/ml Normocin (Invivogene), 2 ⁇ g/ml of puromycin, 500 ⁇ g/ml of geneticin, 15 mM HEPES, pH 7.2.
  • Pathdetect Elk-1 system and human GFRal-expressing plasmid (“Strat-Luc” cells) or empty vector (control cell line “NOStratis”) cells were selected and maintained in the DMEM, 10% FBS, 100 ⁇ g/ml Normocin (Invivogene), 2 ⁇ g/ml of puromycin, 500 ⁇ g/ml of G418, 2 ⁇ g/ml of blasticidin S, 15 mM HEPES, pH 7.2.
  • Cells were plated on 96-well plates in cell density 20 000 cells per well in DMEM, 10% FBS, 100 ⁇ g/ml Normocin, 2 ⁇ g/ml puromycin, 500 ⁇ g/ml of G418, 15 mM HEPES, pH 7.2 one day before assay. The following day, neurotrophic factors in the final concentration of 100 ng/ml were added to the wells in DMEM, 10% FBS, 100 ⁇ Normocin. Cell were allowed to produce luciferase for 24 h, than lysed in 20 ⁇ of lxCell culture lysis reagent (Pro mega) and freeze-thawed once to ensure complete lysis.
  • GDNF was added to the cell suspension before plating until the final concentration 10- 100 ng/ml, then cells were plated on 96-well plate in the cell density 20 000 cells/well and left for 24 h to produce luciferase; for dose- response curves GFLs were added to the final concentration 5-200 ng/ml; to determine the optimal time required to produce luciferase cells were left in the culture with GDNF for 4- 48 hours; to study the short-term MAPK activation, aLUC cells were treated with 100 ng/ml of GDNF for 0.5-60 min, washed once with the growth media and left in the fresh portion of growth medium for 24 hours to produce luciferase. Data are presented as M+m, where M represents an average from 4 repeats and m is standard deviation. The results of the detection are given in Fig. 2. The compounds studied included the following
  • Anti-pY antibodies (clone 4G10, Upstate) diluted 1: 1000 in Binding buffer (TBS, 1% TritonXlOO, 2 % glycerol, 2% BSA ) were added (100 ⁇ /well) and incubate 1-1.5 h at room temperature. Then washed three times with Washing buffer, 200 ⁇ /well. Secondary anti-mouse HRP- conjugated antibodies (Dako) at 1:3000 dilution in Binding Buffer were added at
  • aLUC and NOa cells plated on 35 mm tissue culture dishes were starved for 4 hours in serum- free DMEM and stimulated with 500 ng/ml of PSPN or 100 ng/ml of
  • GDNF (positive control) for 15 min. Then cells were washed once with ice-cold PBS containing 1 mM Na3V04 and lysed on ice in 1 ml per well of RIPA-modified buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% NP-40, 1% TX-100, 10% glycerol, EDTA-free protease inhibitor cocktail (Roche), ImM Na3V04, 2.5 mg/ml of sodium deoxycholate, 1 mM PMSF.
  • RET was immunoprecipitated by anti-RET C-20 antibodies (Santa-Cruz Biotechnology, Inc.).
  • Precipitated proteins were resolved on 7.5% SDS-PAGE and then transferred onto a nitrocellulose membrane.
  • Membrane was blocked for 15 min at room temperature by 10% nonfat dry milk in TBS-T and probed with anti- phosphotyrosine antibodies (clone 4G10, Upstate Biotechnology) diluted 1: 1000 in TBS-T containing 3% nonfat dry milk for 2 hours at room temperature.
  • the membranes were washed 3 times for 5 min in TBS-T and incubated in the 1:3000 solution of secondary anti- mouse antibodies conjugated with HRP (DAKO) diluted in TBS-T containing 3% nonfat dry milk for 45 min at room temperature.
  • Membranes were washed with TBS-T for 5x10 min.
  • Cells were plated on 96- well plates (or 384- well) in cell density 20 000 (or 5 000 for 384-well format) cells per well in DMEM, 10% FBS, 100 ⁇ g/ml Normocin, 2 ⁇ g/ml puromycin, 500 ⁇ g/ml of G418, 15 mM HEPES, pH 7.2 one day before assay. The following day, the compounds were added to a final concentration of 1-50 ⁇ . Structures of the compounds are shown in the description of Figure 5, above. Cells were allowed to produce luciferase for 24 h, then lysed in 20 ⁇ of lxCell culture lysis reagent (Promega) and freeze-thawed once to ensure complete lysis. Then 5 ⁇ of the lysate was mixed (on ice) with 20 ⁇ of luciferase assay substrate (Promega) in a well of black Isoplate
  • Luminescence was counted on MicroBeta 2 counter (PerkinElmer) twice. Data are presented as fold induction, where the corresponding concentration of DMSO was used as a reference. See Figure 5 for data.
  • MG87RET cells were plated on 35 mm tissue culture dishes the day before the experiment. Cells were transfected with GFRal, GFRa3 or with an vector encoding for
  • All rats are exposed to a i.p. injections of active compounds (i.e. GFL-mimetics or RET-signaling activators) and/or to stereotaxic microinfusion twice; first rats are given either vehicle (4 ⁇ ), active compounds (1-100 mg/kg) or GDNF (10 ⁇ g) and 6 hours later each animal receives 6-OHDA (8 ⁇ g) to the same site in left dorsal Striatum.
  • active compounds i.e. GFL-mimetics or RET-signaling activators
  • D/V -4 according to the atlas of Paxinos and Watson (Paxinos and Watson, 1997, The rat brain in stereotaxic coordinates, Academic press, San Diego).
  • the study consisted of following groups: intra striatal PBS+6-OHDA, intra striatal GDNF+6-OHDA and intrastriatal GFL-mimetics+6-OHDA, intra striatal PBS +6-OHDA + i.p. GFL-mimetics.
  • Rotational Behavior Behavioral tests are carried out 2 and 4 weeks postlesion. The rats are allowed to habituate to the test chamber for 30 min before D-amphetamine (University Pharmacy, Helsinki, Finland; 2.5 mg/kg i.p) is administrated. The number of full (360°) ipsilateral and contralateral turns is recorded for a period of 2 h. Net ipsilateral turns to the lesion is calculated by subtracting the turns to the left from the turns to the right.
  • cryoprotectant solution 0.5M PB, 30% glycerol and 30% ethylenglycole
  • Free-floating sections are processed for TH- immunohistochemistry. Following three rinses in PBS, endogenous peroxidase activity is quenched in 3% ⁇ 2 ⁇ 2 /10% methanol/PBS for 5 minutes. After 3 rinses in PBS, sections are preincubated with normal horse serum (NHS)/0.3% Triton X-100 in PBS in order to block nonspecific staining. Thereafter, sections are incubated overnight at room
  • Morphological Analysis / SN Cell Counts Unbiased stereological cell counting procedures are used to count TH-positive cells in the substantia nigra pars compacta (SNpc) by using the optical fractionator method in combination with the dissector principle and unbiased counting rules (West et al., 1991, Anat. Rec. 231, 482-497; Mouton et al., 2002, Brain Res. 956, 30-35). The entire SNpc is analyzed with Stereo Investigator platform (MicroBrightField, Germany) attached to Olympus BX51 microscope.
  • Optical fractionator estimation method is optimized to give coefficient of error less than x % per individual brain sample.
  • Each reference space is outlined at low power (4x), and cells are counted using a high magnification (60x, oil immersion) objective.
  • dopaminergic nerves of the Nigro-Striatal tract Under anesthesia, the rats are exposed to a stereotaxic microinjection twice. First, they are given either vehicle (PBS, 4 ⁇ , the control group) or active compounds and 6 hours later each animal receives 6-OHDA (8 ⁇ g) to the same site in left dorsal Striatum.
  • vehicle PBS, 4 ⁇ , the control group
  • active compounds 6 hours later each animal receives 6-OHDA (8 ⁇ g) to the same site in left dorsal Striatum.
  • the coordinates in the left striatum relative to the bregma and dura are A/P+1.0, L/M+2.7, D/V-4 according to the atlas of Paxinos and Watson (Paxinos and Watson, 1997, The rat brain in stereotaxic coordinates, Academic press, San Diego).
  • Behavioral tests are carried out twice in all rats. Two and 4 weeks post lesion each rat is given D-amphetamine (2.5 mg/kg, i.p.) in order to induce ipsilateral (to the side of lesion) turning behavior, which is recorded for a period of 2 h. At two weeks post lesion, it is expected that amphetamine (2.5 mg/kg, i.p.) induces significant ipsilateral turning behavior in the control group. On the contrary, it is expected that minimum or no increase in ipsilateral turns is observed in the treatment group (treated with active compounds prior to 60HDA). At four weeks post-lesion, it is expected that active compounds are able to significantly reverse the amphetamine induced ipsilateral turning, and the immunohistochemical analysis shows significant protection of DAergic cells by the neurotrophic factor.
  • TH-immunohistochemistry At 4 weeks post lesion, following the second behavioral experiment, the rats are anesthetized with an overdose of sodium pentobarbital (90 mg/kg) and perfused intracardially with phosphate-buffered saline (PBS) followed by 4% paraformaldehyde in 0.1 M sodium phosphate buffer, pH 7.4. Freefloating sections will be processed for TH-immunohistochemistry. Unbiased stereological cell counting procedures is used to count TH-positive cells in the substantia nigra pars compacta (SNpc) by using the optical fractionator method in combination with the dissector principle and unbiased counting rules (West et al. 1991, Anat. Rec.
  • the objective of this study is to investigate the effect of intrastriatally (i.s.) administered small molecule GDNF mimetics (compounds 13, 16, 319H6 and 292651, structures shown in the description of the Figures, above) in a rat model 6-OHDA of Parkinson's disease.
  • small molecule GDNF mimetics compounds 13, 16, 319H6 and 292651, structures shown in the description of the Figures, above
  • 6-OHDA substantia nigra
  • GDNF mimetics compounds GDNF or vehicle is administered to the striatum at 3 weeks after the exposure to the neurotoxin 6-OHDA.
  • the selective damage to dopaminergic neurons in the SNc, as well as striatal levels of dopamine and its metabolites are evaluated 12 weeks after the injection of 6-OHDA with tyrosine hydroxylase (TH) immunohistochemistry and HPLC, respectively.
  • TH tyrosine hydroxylase
  • the behavioral impairment of rats is evaluated by forelimb asymmetry test (cylinder test), amphetamine induced rotation asymmetry test and Y-maze test for stereotypic spontaneous rotation deficits.
  • Group 1 12 rats treated with Vehicle (0 mg/kg, i.s.) at 3 weeks after 6-OHDA infusion
  • Group 2 12 rats treated with BT13 (5 ug per rat i.e. 0.4 mg/kg, i.s.) at 3 weeks after 6- OHDA infusion
  • Group 3 12 rats treated with BT13 (1 ug per rat i.e. 0.1 mg/kg, i.s.) at 3 weeks after 6- OHDA infusion
  • Group 4 12 rats treated with BT13 (0.2 ug per rat i.e. 0.2 mg/kg, i.s.) at 3 weeks after 6- OHDA infusion
  • Group 5 12 rats treated with BT16 (0.5 ug per rat i.e. 0.2 mg/kg, i.s.) at 3 weeks after 6- OHDA infusion
  • Group 6 12 rats treated with BT292651 (5 ug per rat i.e.0.4 mg/kg, i.s.) at 3 weeks after 6- OHDA infusion
  • Group 7 12 rats treated with BT292651 (1 ug per rat i.e. 0.1 mg/kg, i.s.) at 3 weeks after 6-OHDA infusion
  • Group 8 12 rats treated with BT18 (1 ug per rat i.e. 0.2 mg/kg, i.s.) at 3 weeks after 6- OHDA infusion
  • Group 9 12 rats treated with GDNF (R& D Systems, Ltd.; lOug per rat, or about 40ug/kg, i.s.) at 3 weeks after 6-OHDA infusion
  • 6-OHDA lesioning is carried out according to Sauer and Oertel with modifications (Sauer and Oertel, 1994).
  • Male Wistar rats are anesthetized with 5% isoflurane (in 70% N 2 0 and 30% 0 2 ; flow 300 ml/min) and placed in a stereotactic frame. During the operation
  • concentration of anesthetic is reduced to 1-1.5%.
  • the rectal temperature is maintained at 37.0 + 1.0°C with a homeothermic blanket system.
  • the right brain hemisphere is exposed through a small craniectomy to the skull.
  • the dura mater is carefully removed with fine forceps and a stereotaxic injection of 6-OHDA (4 ⁇ g/ ⁇ l) is made into the right striatum.
  • a total of 7 ⁇ of 6-OHDA is infused at a speed of 0.5 ⁇ /min and is equally distributed between 4 sites at the following coordinates: AP +1.0, ML +2.8, DV -6.0, -5.5, -5.0 and - 4.4 mm.
  • the cannula is left in place for another 5 min before being withdrawn.
  • the hole in the skull is subsequently filled with repair material and the skin is closed and disinfected.
  • the rats are allowed to recover from anesthesia and are carefully monitored for possible post surgical complications.
  • the animals are returned to the home cages with ad libitum access to food and water.
  • rats are re-anesthetized with 5% isoflurane (in 70% N 2 0 and 30% 0 2 ; flow 300 ml/min) and placed in a stereotactic frame. During the operation
  • concentration of anesthetic is reduced to 1-1.5%.
  • the rectal temperature is maintained at 37.0 + 1.0°C with a homeothermic blanket system.
  • the right brain hemisphere is exposed through a small craniectomy to the skull.
  • a stereotaxic injection of the test compound, GDNF or vehicle is made into the right striatum.
  • Each dosing solution is infused at a speed of 1 ⁇ /min and is equally distributed between 4 sites at the following coordinates: AP +1.0, ML +2.8, DV -6.0, -5.5, -5.0 and -4.4 mm.
  • the cannula is left in place for another 5 min before being withdrawn.
  • the hole in the skull is subsequently filled with repair material and the skin is closed and disinfected.
  • the rats are allowed to recover from anesthesia and are carefully monitored for possible post surgical complications.
  • the animals are returned to the home cages with ad libitum access to food and water.
  • Behavioral Testing Forelimb Use and Preference in Spontaneous Rearing - Cylinder Test: The cylinder test (modified from Schallert and Tillerson in innovative models of CNS disease: from molecule to therapy. Clifton, NJ, Humana, 1999) is used to quantify the forelimb use for spontaneous rearing on the home cage wall. The test is performed on days 14, 35, 56 and 77 days after the 6-OHDA injection. The rats are monitored as they move freely in their home cage. Contacts made by each forepaw with the cage wall while rearing are scored by a blinded observer to the treatment. A total of 20 contacts are recorded for each animal, and the number of impaired and non-impaired forelimb contacts as percentage of total contacts is calculated.
  • the Y-maze is made of black painted plastic. Each arm of the Y-maze is 35 cm long, 25 cm high and 10 cm wide and positioned at an equal angle. 14, 35, 56 and 77 days after 6-OHDA lesioning, each rat is placed at the end of one arm and allowed to move freely through the maze for an 8-min session. The sequence of arm entries is recorded manually. Rats with unilateral 6-OHDA lesion tend to turn away from the side of higher dopamine activity (unlesioned, left) and therefore show bias for right turnings. The percentage of right turning preference is determined from the data set as the percentage of right turns over all turns ((right/left+right) x 100%). In addition to right turning preference scores, total number of arm entries is measured.
  • the animals are tested for amphetamine-induced rortation behavior on days 42 and 84 days after the 6-OHDA injection. Motor asymmetry is monitored in automated rotometer bowls (TSE Systems, Germany) for 45 min after injection of amphetamine (5 mg/kg i.p.). The net ipsiversive rotation asymmetry score for each test is calculated by subtracting contralateral turns from the ipsilateral turns to the lesion.
  • Ipsi- and contralateral striatum is dissected out in toto, weighed, snap-frozen on dry ice, and stored at -80°C for the HPLC analysis of dopamine and its metabolites. All ipsilateral striatum samples are subjected to HPLC analysis. Contralateral samples are not subjected to HPLC analysis.
  • the posterior brain block containing the SNc is fixed by immersion in 4% paraformaldehyde in 0.1 M phosphate buffer (PB) for 24 hours. Following cryoprotection in 30% sucrose in 0.1M PB for 2-3 days and freezing the blocks in liquid nitrogen, 20- ⁇ - thick cryosections are prepared with a cryostat. From each rat 4 sections in one
  • SuperfrostTM glass slide (sections 100 ⁇ apart) are used for TH immunohistochemistry (4 extra glass slides each containing 4 sections are also collected and stored in -80°C as spare samples). The sections are first re-hydrated and then permeabilized in PBS containing 0.5% Tween-20. The sections are blocked in 5% goat serum in PBST (PBS with 0.05% Tween 20), followed by overnight incubation with 1: 1500 rabbit anti-TH (Novus
  • Biologicals cat# NB300-109 polyclonal antibody at RT. Thereafter the sections are washed, and incubated with Alexa Fluor® 594 conjugated goat anti-rabbit IgG secondary antibody (Molecular Probes cat# A11012) for 2 h at RT. Finally, the sections are rinsed, dehydrated, coverslipped and examined with Olympus AX-70 fluorescence microscope. The number of TH- immunofluorescent neurons is counted through the SNc (4 sections per animal).
  • Ipsilateral striata are subjected to HPLC.
  • Dopamine (DA), 3,4- dihydroxyphenylacetic acid (DOPAC) and homo vanillic acid (HVA) concentrations in striatal tissue samples are determined by high performance liquid chromatography (HPLC) method with electrochemical detection.
  • tissue samples are homogenized (1: 10, w/v) in 0.1 M perchloric acid with MSE Soniprep 150 ultrasonic disintegrator (MSE Scientific).
  • the ESA HPLC system (ESA Inc., Chelmsford, MA, USA) consists of a 582 solvent delivery system, a DG-1210 vacuum degasser, an 542 autosampler, a 880 thermostatted chamber, an eight-channel CoulArray® 5600 electrochemical array detector equipped with a two-channel 5014B microdialysis cell and a CoulArray® for Windows data acquisition module (version 1.00).
  • the applied potentials are -175 mV (channel 1), +225 mV (channel 2), +350 mV (channel 3) and +450 mV (channel 4).
  • DA and DOPAC are detected on channel 2 and HVA on channel 3. Injection volume is 10 ⁇ .
  • the analytes are separated on a Zorbax SB-Aq reversed-phase column (2.1 x 100 mm, 3.5 ⁇ , Agilent Technologies Inc., Little Falls, Wilmington, DE, USA) with a Zorbax SB-Aq precolumn (2.1 x 12.5 mm, 5 ⁇ ) in an isocratic run.
  • the column is maintained at 35°C.
  • the mobile phase is 100 mM monobasic sodium phosphate containing 4.75 mM citric acid monohydrate, 7 mM 1-octanesulfonic acid and 50 ⁇ disodium EDTA - acetonitrile mixture (98:2, v/v).
  • the pH of the mobile phase is adjusted to 2.2 with o- phosphoric acid.
  • the flow rate is 0.3 ml/min.
  • the levels of DA, DOPAC and HVA are expressed as nmol/g wet tissue.
  • GDNF mimetics compounds BT13, BT16, BT18 and BT292651 when injected 3 weeks after the injection to 6-OHDA neurotoxin into the striatum significantly reduce amphetamine-induced ipsilateral rotation of lesioned rats.
  • compounds BT13, BT16, BT18 and BT292651 significantly reduce pathological motoric movement in rat model of Parkinson's disease in vivo.
  • Rat dopaminergic neurons were cultured as described by Schinelli et al., 1988. Briefly pregnant female rats of 15 days gestation were killed by cervical dislocation (Rats Wistar; Janvier) and the fetuses removed from the uterus. The embryonic midbrains were removed and placed in ice-cold medium of Leibovitz (LI 5; Invitrogen) containing 1% of Penicillin-Streptomycin (PS; Invitrogen) and 1% of bovine serum albumin (BSA; Sigma). Only the ventral portions of the mesencephalic flexure were used for the cell preparations as this is the region of the developing brain rich in dopaminergic neurons.
  • Leibovitz LI 5; Invitrogen
  • PS Penicillin-Streptomycin
  • BSA bovine serum albumin
  • the midbrains were dissociated by trypsinisation for 20 min at 37°C (10% of trypsin EDTA 10X; Invitrogen) diluted in PBS without calcium and magnesium. The reaction was stopped by the addition of Dulbecco's modified Eagle's medium (DMEM; Invitrogen) containing DNAase I grade II (0.1 mg/ml; Roche Diagnostic;) and 10% of fetal calf serum (FCS; Invitrogen). Cells were then mechanically dissociated by 3 passages through a 10 ml pipette. Cells were then centrifuged at 180 x g for 10 min at room temperature on a layer of BSA (3.5%) in L15 medium.
  • DMEM Dulbecco's modified Eagle's medium
  • FCS fetal calf serum
  • the supernatant was discarded and the cells of pellet were re-suspended in a defined culture medium consisting of Neurobasal (Invitrogen) supplemented with B27 (2%; Invitrogen), L-glutamine (0.2 mM; Invitrogen) and 1% of PS solution. Viable cells were counted in a Neubauer cytometer using the trypan blue exclusion test.
  • the cells were seeded at a density of 69 000 cells/well in 96 well-plates (wells were pre-coated with poly-L-lysine (10 ⁇ g/ml; Sigma)) and were cultured at 37°C in a humidified air (95 )/C0 2 (5%) atmosphere. Half of the medium was changed every 2 days with fresh medium. In these conditions, after 5 days of culture, astrocytes were present in the culture and release growth factor allowing neurons differentiation. Three to five percent of the neuronal cell population were dopaminergic neurons.
  • BDNF concentration is in ng/mL
  • test compounds were transferred into in 384- well culture plate using Echo acoustic dispenser (Labcyte Inc.) in 2.5 - 125 nl volume. Trypsinized MG87RET murine fibroblasts were seeded at 20 000 cells/ml (500 cells/well) in the presence of each compound dissolved in DMSO at the indicated concentratino. After brief mixing on a horizontal shaker, the plates were centrifuged and transferred into the incubator. Two days (48 hours) after addition of cells to compounds, the viability of the cells was evaluated using CelTiterGlo reagent (Promega). The results are shown in Figure 8.
  • ALS e.g. SOD1G93A rat model
  • cerebral ischemia e.g. middle cerebral artery ligation rodent model
  • Alzheimer's disease e.g., ⁇ -overexpressing transgenic mouse model
  • chronic pain e.g. spinal nerve ligation rat model
  • Airavaara et al. 2004. Increased extracellular dopamine concentrations and FosB/DeltaFosB expression in striatal brain areas of heterozygous GDNF knockout mice. Eur J Neurosci. 20:2336-44.
  • GDNF a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science. 260: 1130-2. [0140] Lindholm, et al. 2007. Novel neurotrophic factor CDNF protects and rescues midbrain dopamine neurons in vivo. Nature. 448:73-7.
  • CERE- 120 adeno-associated virus serotype 2-neurturin
  • RET (MEN 2B) is active in the endoplasmic reticulum before reaching the cell surface. Oncogene. 26:7909-7915.

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Quinoline Compounds (AREA)

Abstract

La présente invention concerne des composés et des procédés destinés à traiter des troubles neurologiques ainsi que d'autres troubles en administrant à un sujet qui en a besoin une quantité efficace d'un composé se liant spécifiquement à, et/ou modulant spécifiquement, des molécules de récepteur GFRα, qui peuvent être des mimétiques de ligands (GFL) de la famille du facteur neurotrophique dérivé des cellules gliales (GDNF), d'agonistes de la voie de signalisation GFRα/RET, et/ou des agonistes directs du RET (activateurs).
PCT/EP2010/069535 2009-12-11 2010-12-13 Procédés destinés à faciliter la survie de cellules neuronales en utilisant des mimétiques de ligands de la famille des gdnf (gfl) ou des activateurs de la voie de signalisation du ret WO2011070177A2 (fr)

Priority Applications (8)

Application Number Priority Date Filing Date Title
JP2012542580A JP2013513588A (ja) 2009-12-11 2010-12-13 Ｇｄｎｆファミリーリガンド（ｇｆｌ）のミメティックまたはｒｅｔシグナル経路活性化因子を用いた、神経系細胞の生存を容易にするための方法
CN2010800637467A CN103180297A (zh) 2009-12-11 2010-12-13 使用gdnf家族配体(gfl)模拟剂或ret信号传导通路活化剂促进神经细胞存活的方法
CA2783934A CA2783934A1 (fr) 2009-12-11 2010-12-13 Procedes destines a faciliter la survie de cellules neuronales en utilisant des mimetiques de ligands de la famille des gdnf (gfl) ou des activateurs de la voie de signalisation du ret
BR112012014022A BR112012014022A2 (pt) 2009-12-11 2010-12-13 composto, composição, dispositivo médico e método ex vivo para modulação do crescimento de um neurônico
EP10790954.1A EP2509953B1 (fr) 2009-12-11 2010-12-13 Procédés destinés à faciliter la survie de cellules neuronales en utilisant des mimétiques de ligands de la famille des gdnf (gfl) ou des activateurs de la voie de signalisation du ret
MX2012006580A MX2012006580A (es) 2009-12-11 2010-12-13 Metodo para facilitar la sobrevivencia de celulas neurales usando mimeticos de ligandos (gfl) de la familia gdnf o activadores de la ruta de señalizacion de ret.
AU2010329847A AU2010329847A1 (en) 2009-12-11 2010-12-13 Methods of facilitating neural cell survival using GDNF family ligand (GFL) mimetics or RET signaling pathway activators
US13/514,906 US8901129B2 (en) 2009-12-11 2010-12-13 Methods of facilitating neural cell survival using GDNF family ligand (GFL) mimetics or RET signaling pathway activators

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28585809P 2009-12-11 2009-12-11
US61/285,858 2009-12-11

Publications (2)

Publication Number Publication Date
WO2011070177A2 true WO2011070177A2 (fr) 2011-06-16
WO2011070177A3 WO2011070177A3 (fr) 2011-09-01

Family

ID=43502911

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2010/069535 WO2011070177A2 (fr) 2009-12-11 2010-12-13 Procédés destinés à faciliter la survie de cellules neuronales en utilisant des mimétiques de ligands de la famille des gdnf (gfl) ou des activateurs de la voie de signalisation du ret

Country Status (9)

Country Link
US (1) US8901129B2 (fr)
EP (1) EP2509953B1 (fr)
JP (1) JP2013513588A (fr)
CN (2) CN103180297A (fr)
AU (1) AU2010329847A1 (fr)
BR (1) BR112012014022A2 (fr)
CA (1) CA2783934A1 (fr)
MX (1) MX2012006580A (fr)
WO (1) WO2011070177A2 (fr)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103146798A (zh) * 2013-02-25 2013-06-12 潍坊易思特生物科技有限公司 一种测定重组人胶质细胞源性神经营养因子活性的细胞学方法
WO2014041179A1 (fr) * 2012-09-17 2014-03-20 Chemedest Ltd. Traitement d'une neuropathie périphérique à l'aide d'agonistes du récepteur de type 3 de gfr(alpha)3
CN105640955A (zh) * 2016-01-28 2016-06-08 昆明医科大学 一种Aminoquinol的新用途
WO2017195042A1 (fr) 2016-05-13 2017-11-16 Instituto De Medicina Molecular Méthodes de traitement de maladies associées à des cellules ilc3
WO2022207846A1 (fr) 2021-03-31 2022-10-06 Cambridge Enterprise Limited Inhibiteurs thérapeutiques de la signalisation gdf15
WO2022254255A1 (fr) 2021-06-03 2022-12-08 Fundacao D. Anna De Sommerchampalimaud E Dr. Unités neuro-mésenchymes de lutte contre l'ilc2 et l'obésité par l'intermédiaire d'un circuit du cerveau-adipeux
WO2024023287A1 (fr) * 2022-07-28 2024-02-01 Genecode Dérivés de [4-[5-(méthylsulfonyl)-phényl]pipérazin-1-yl]-(phényl)méthanone et composés similaires ayant une activité gfr alpha 1-ret utilisés en tant qu'agents neuroprotecteurs pour le traitement de troubles neurologiques
WO2024023284A1 (fr) 2022-07-28 2024-02-01 Genecode Nouveaux sulfonamides et leur utilisation en tant qu'agents neuroprotecteurs et/ou neurorestorateurs
WO2024079351A1 (fr) 2022-10-14 2024-04-18 Genecode Nouveaux sulfonamides à base de pipérazine et leur utilisation comme agents neuroprotecteurs et/ou neurorestorateurs

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105906608B (zh) * 2016-05-03 2018-10-19 中山大学 8-氨基喹啉-松果体素杂联体及其药物组合物
AU2017380583A1 (en) * 2016-12-21 2019-06-27 AlzeCure Pharma AB Triazinetrione derivatives and their use as modulators of neurotrophin receptor and receptor tyrosine kinases
CN107337641B (zh) * 2017-07-01 2020-04-28 广东医科大学 一种4-柔性胺基-2-芳乙烯基喹啉类衍生物及其制备方法和应用
CA3237424A1 (fr) 2021-11-12 2023-05-19 Axent Biosciences Inc. Procedes de production de neurones fonctionnels

Citations (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4426330A (en) 1981-07-20 1984-01-17 Lipid Specialties, Inc. Synthetic phospholipid compounds
US4534899A (en) 1981-07-20 1985-08-13 Lipid Specialties, Inc. Synthetic phospholipid compounds
WO1988007851A1 (fr) 1987-04-06 1988-10-20 Innovative Therapeutics Corporation Bloqueurs de recepteurs de n-methyle-d-aspartate emprisonnes dans des liposomes
WO1988007852A1 (fr) 1987-04-06 1988-10-20 Innovative Therapeutics Corporation Magnesium emprisonne dans des liposomes
WO1989007938A1 (fr) 1988-02-26 1989-09-08 Shashoua Victor E Conjugue medicamenteux d'acide gras administrant le medicament a travers la barriere vasculaire du cerveau
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4933324A (en) 1988-02-26 1990-06-12 Shashoua Victor E Fatty acid-neuroactive drug conjugate as a prodrug
WO1991004014A1 (fr) 1989-09-21 1991-04-04 Synergen, Inc. Procede de transport de compositions a travers la barriere hemato-encephalique
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5019400A (en) 1989-05-01 1991-05-28 Enzytech, Inc. Very low temperature casting of controlled release microspheres
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5112596A (en) 1990-04-23 1992-05-12 Alkermes, Inc. Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability
US5112863A (en) 1989-12-05 1992-05-12 Nippon Oil & Fats Co., Ltd. Antipsychotic drug
US5154924A (en) 1989-09-07 1992-10-13 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical agent conjugates
US5182107A (en) 1989-09-07 1993-01-26 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates
WO1993010819A1 (fr) 1991-11-26 1993-06-10 Alkermes, Inc. Procede de preparation de conjugues d'agents diagnostiques ou neuropharmaceutiques-anticorps specifiques de recepteur de transferine
US5227170A (en) 1989-06-22 1993-07-13 Vestar, Inc. Encapsulation process
US5260308A (en) 1991-11-06 1993-11-09 Mayo Foundation For Medical Education And Research Method to increase permeability of the blood-nerve/brain barriers to proteins
US5264221A (en) 1991-05-23 1993-11-23 Mitsubishi Kasei Corporation Drug-containing protein-bonded liposome
US5268164A (en) 1990-04-23 1993-12-07 Alkermes, Inc. Increasing blood-brain barrier permeability with permeabilizer peptides
US5271961A (en) 1989-11-06 1993-12-21 Alkermes Controlled Therapeutics, Inc. Method for producing protein microspheres
WO1994002178A1 (fr) 1992-07-27 1994-02-03 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Ciblage de liposomes sur la barriere hemato-encephalique
US5284876A (en) 1988-02-26 1994-02-08 Neuromedica, Inc. Method of treating tardive dyskinesia using dopaminergic agents of prodrugs of therapeutic agents
US5354844A (en) 1989-03-16 1994-10-11 Boehringer Ingelheim International Gmbh Protein-polycation conjugates
US5356633A (en) 1989-10-20 1994-10-18 Liposome Technology, Inc. Method of treatment of inflamed tissues
WO1995002421A1 (fr) 1993-07-16 1995-01-26 Alkermes, Inc. Proteines de fusion a ligand specifique du recepteur de la transferrine et a agent neuropharmaceutique
US5395619A (en) 1993-03-03 1995-03-07 Liposome Technology, Inc. Lipid-polymer conjugates and liposomes
US5413797A (en) 1992-03-12 1995-05-09 Alkermes Controlled Therapeutics, Inc. Controlled release ACTH containing microspheres
US5417978A (en) 1993-07-29 1995-05-23 Board Of Regents, The University Of Texas System Liposomal antisense methyl phosphonate oligonucleotides and methods for their preparation and use
US5459127A (en) 1990-04-19 1995-10-17 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US5462854A (en) 1993-04-19 1995-10-31 Beckman Instruments, Inc. Inverse linkage oligonucleotides for chemical and enzymatic processes
US5469854A (en) 1989-12-22 1995-11-28 Imarx Pharmaceutical Corp. Methods of preparing gas-filled liposomes
US5512295A (en) 1994-11-10 1996-04-30 The Board Of Trustees Of The Leland Stanford Junior University Synthetic liposomes for enhanced uptake and delivery
US5521291A (en) 1991-09-30 1996-05-28 Boehringer Ingelheim International, Gmbh Conjugates for introducing nucleic acid into higher eucaryotic cells
US5527528A (en) 1989-10-20 1996-06-18 Sequus Pharmaceuticals, Inc. Solid-tumor treatment method
US5534259A (en) 1993-07-08 1996-07-09 Liposome Technology, Inc. Polymer compound and coated particle composition
US5543152A (en) 1994-06-20 1996-08-06 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
US5547932A (en) 1991-09-30 1996-08-20 Boehringer Ingelheim International Gmbh Composition for introducing nucleic acid complexes into higher eucaryotic cells
US5556948A (en) 1993-01-22 1996-09-17 Mitsubishi Chemical Corporation Phospholipid derivatized with PEG bifunctional linker and liposome containing it
US5580575A (en) 1989-12-22 1996-12-03 Imarx Pharmaceutical Corp. Therapeutic drug delivery systems
US5583020A (en) 1992-11-24 1996-12-10 Ribozyme Pharmaceuticals, Inc. Permeability enhancers for negatively charged polynucleotides
US5591721A (en) 1994-10-25 1997-01-07 Hybridon, Inc. Method of down-regulating gene expression
US5595756A (en) 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US6287860B1 (en) 2000-01-20 2001-09-11 Isis Pharmaceuticals, Inc. Antisense inhibition of MEKK2 expression
US7182202B2 (en) 2005-05-31 2007-02-27 Franz Grimme Landmaschinenfabrik Gmbh & Co. Kg Conveying device for bulk material
US20070060526A1 (en) 2005-06-08 2007-03-15 Longo Frank M Methods of facilitating neural cell survival using non-peptide and peptide BDNF neurotrophin mimetics
US10867398B2 (en) 2017-11-21 2020-12-15 Reliance Core Consulting LLC Methods, systems, apparatuses and devices for facilitating motion analysis in an environment

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2531011A (en) 1949-01-22 1950-11-21 Sterling Drug Inc 3-chloro-9-[2-(2-hydroxyethylamino)-ethylamino] acridine and method for its production
US3232945A (en) 1962-08-13 1966-02-01 S E Massengill Company 7,8,9,10-tetrahalo-6h-cyclohepta-(b)-quinolines
US3458525A (en) * 1966-07-01 1969-07-29 American Home Prod Spiro(indoline-3,2'-thiazolidine)-2-one and derivatives
DK569087A (da) * 1986-10-31 1988-05-01 Sumitomo Pharma Quinolin-derivater, deres fremstilling og anvendelse
US4999430A (en) * 1989-07-31 1991-03-12 Warner-Lambert Company Derivatives of 1,2,3,4-tetrahydro-9-acrisinamine
CA2029497C (fr) 1989-11-08 2002-06-04 Kunihiro Ninomiya (Deceased) Derive 4-acylaminopyridine
US5109921A (en) 1991-04-29 1992-05-05 Halliburton Company Controlled weak point for wireline cable
ATE321882T1 (de) 1997-07-01 2006-04-15 Isis Pharmaceuticals Inc Zusammensetzungen und verfahren zur verabreichung von oligonukleotiden über die speiseröhre
US6235769B1 (en) 1997-07-03 2001-05-22 Sugen, Inc. Methods of preventing and treating neurological disorders with compounds that modulate the function of the C-RET receptor protein tyrosine kinase
AU3243300A (en) 1999-02-23 2000-09-14 Isis Pharmaceuticals, Inc. Multiparticulate formulation
FI20000480A0 (fi) 2000-03-01 2000-03-01 Orion Yhtymae Oyj Kinoliini- ja naftaleenijohdannaisia alfa-2 antagonisteina
US7001905B2 (en) * 2000-03-15 2006-02-21 Warner-Lambert Company Substituted diarylamines as MEK inhibitors
WO2004004660A2 (fr) 2002-07-09 2004-01-15 Alpha Research Group, L.L.C. Compositions et procede pour traiter la maladie de parkinson et la diskynesie tardive
US20040034019A1 (en) * 2002-08-08 2004-02-19 Ronald Tomlinson Piperazine and piperidine derivatives
WO2004033434A1 (fr) 2002-10-09 2004-04-22 Pfizer Products Inc. Composes pyrazole pour le traitement de maladies neurodegeneratives
JP2007506741A (ja) * 2003-09-23 2007-03-22 メルク　エンド　カムパニー　インコーポレーテッド 向代謝性グルタミン酸受容体のピラゾール系調節剤
WO2005113523A1 (fr) 2004-05-20 2005-12-01 Foldrx Pharmaceuticals, Inc. Composés 2-(hétéroaryl)benzoxazoles et dérivés, compositions et procédés servant à stabiliser la transthyrétine et à inhiber le mauvais repliement de la transthyrétine
AU2006218405A1 (en) 2005-03-03 2006-09-08 Sirtris Pharmaceuticals, Inc. Acridine and quinoline derivatives as sirtuin modulators
GB0505086D0 (en) * 2005-03-11 2005-04-20 Glaxo Group Ltd Compounds
JP5388574B2 (ja) 2005-05-31 2014-01-15 バーテックス ファーマシューティカルズ インコーポレイテッド イオンチャネルのモジュレーターとして有用なヘテロ環式類
WO2008010984A2 (fr) * 2006-07-17 2008-01-24 The Trustees Of The University Of Pennsylvania Activation de p53 par l'acridine et utilisations correspondantes
US7605265B2 (en) 2007-01-22 2009-10-20 Biotechnology Research Corporation Ltd. Heterodimers and methods of using them
US20080234267A1 (en) * 2007-03-20 2008-09-25 Karen Elizabeth Lackey Compounds and Methods of Treatment
CN101784533B (zh) 2007-08-22 2013-08-21 艾博特股份有限两合公司 4-苄基氨基喹啉、含有它们的药物组合物和它们在治疗中的用途
US7863295B2 (en) * 2008-02-12 2011-01-04 Children's Medical Center Corporation Treatments for neuropathy
US20110045100A1 (en) * 2008-03-05 2011-02-24 Georgetown University Antimalarial Quinolines and Methods of Use Thereof

Patent Citations (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4426330A (en) 1981-07-20 1984-01-17 Lipid Specialties, Inc. Synthetic phospholipid compounds
US4534899A (en) 1981-07-20 1985-08-13 Lipid Specialties, Inc. Synthetic phospholipid compounds
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
WO1988007851A1 (fr) 1987-04-06 1988-10-20 Innovative Therapeutics Corporation Bloqueurs de recepteurs de n-methyle-d-aspartate emprisonnes dans des liposomes
WO1988007852A1 (fr) 1987-04-06 1988-10-20 Innovative Therapeutics Corporation Magnesium emprisonne dans des liposomes
WO1989007938A1 (fr) 1988-02-26 1989-09-08 Shashoua Victor E Conjugue medicamenteux d'acide gras administrant le medicament a travers la barriere vasculaire du cerveau
US4933324A (en) 1988-02-26 1990-06-12 Shashoua Victor E Fatty acid-neuroactive drug conjugate as a prodrug
US5284876A (en) 1988-02-26 1994-02-08 Neuromedica, Inc. Method of treating tardive dyskinesia using dopaminergic agents of prodrugs of therapeutic agents
US5354844A (en) 1989-03-16 1994-10-11 Boehringer Ingelheim International Gmbh Protein-polycation conjugates
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5416016A (en) 1989-04-03 1995-05-16 Purdue Research Foundation Method for enhancing transmembrane transport of exogenous molecules
US5019400A (en) 1989-05-01 1991-05-28 Enzytech, Inc. Very low temperature casting of controlled release microspheres
US5227170A (en) 1989-06-22 1993-07-13 Vestar, Inc. Encapsulation process
US5154924A (en) 1989-09-07 1992-10-13 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical agent conjugates
US5182107A (en) 1989-09-07 1993-01-26 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates
WO1991004014A1 (fr) 1989-09-21 1991-04-04 Synergen, Inc. Procede de transport de compositions a travers la barriere hemato-encephalique
US5527528A (en) 1989-10-20 1996-06-18 Sequus Pharmaceuticals, Inc. Solid-tumor treatment method
US5213804A (en) 1989-10-20 1993-05-25 Liposome Technology, Inc. Solid tumor treatment method and composition
US5356633A (en) 1989-10-20 1994-10-18 Liposome Technology, Inc. Method of treatment of inflamed tissues
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5271961A (en) 1989-11-06 1993-12-21 Alkermes Controlled Therapeutics, Inc. Method for producing protein microspheres
US5112863A (en) 1989-12-05 1992-05-12 Nippon Oil & Fats Co., Ltd. Antipsychotic drug
US5580575A (en) 1989-12-22 1996-12-03 Imarx Pharmaceutical Corp. Therapeutic drug delivery systems
US5469854A (en) 1989-12-22 1995-11-28 Imarx Pharmaceutical Corp. Methods of preparing gas-filled liposomes
US5459127A (en) 1990-04-19 1995-10-17 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US5268164A (en) 1990-04-23 1993-12-07 Alkermes, Inc. Increasing blood-brain barrier permeability with permeabilizer peptides
US5112596A (en) 1990-04-23 1992-05-12 Alkermes, Inc. Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability
US5264221A (en) 1991-05-23 1993-11-23 Mitsubishi Kasei Corporation Drug-containing protein-bonded liposome
US5547932A (en) 1991-09-30 1996-08-20 Boehringer Ingelheim International Gmbh Composition for introducing nucleic acid complexes into higher eucaryotic cells
US5521291A (en) 1991-09-30 1996-05-28 Boehringer Ingelheim International, Gmbh Conjugates for introducing nucleic acid into higher eucaryotic cells
US5260308A (en) 1991-11-06 1993-11-09 Mayo Foundation For Medical Education And Research Method to increase permeability of the blood-nerve/brain barriers to proteins
WO1993010819A1 (fr) 1991-11-26 1993-06-10 Alkermes, Inc. Procede de preparation de conjugues d'agents diagnostiques ou neuropharmaceutiques-anticorps specifiques de recepteur de transferine
US5413797A (en) 1992-03-12 1995-05-09 Alkermes Controlled Therapeutics, Inc. Controlled release ACTH containing microspheres
WO1994002178A1 (fr) 1992-07-27 1994-02-03 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Ciblage de liposomes sur la barriere hemato-encephalique
US5583020A (en) 1992-11-24 1996-12-10 Ribozyme Pharmaceuticals, Inc. Permeability enhancers for negatively charged polynucleotides
US5556948A (en) 1993-01-22 1996-09-17 Mitsubishi Chemical Corporation Phospholipid derivatized with PEG bifunctional linker and liposome containing it
US5395619A (en) 1993-03-03 1995-03-07 Liposome Technology, Inc. Lipid-polymer conjugates and liposomes
US5462854A (en) 1993-04-19 1995-10-31 Beckman Instruments, Inc. Inverse linkage oligonucleotides for chemical and enzymatic processes
US5534259A (en) 1993-07-08 1996-07-09 Liposome Technology, Inc. Polymer compound and coated particle composition
WO1995002421A1 (fr) 1993-07-16 1995-01-26 Alkermes, Inc. Proteines de fusion a ligand specifique du recepteur de la transferrine et a agent neuropharmaceutique
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
US5417978A (en) 1993-07-29 1995-05-23 Board Of Regents, The University Of Texas System Liposomal antisense methyl phosphonate oligonucleotides and methods for their preparation and use
US5595756A (en) 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US5543152A (en) 1994-06-20 1996-08-06 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US5591721A (en) 1994-10-25 1997-01-07 Hybridon, Inc. Method of down-regulating gene expression
US5512295A (en) 1994-11-10 1996-04-30 The Board Of Trustees Of The Leland Stanford Junior University Synthetic liposomes for enhanced uptake and delivery
US6287860B1 (en) 2000-01-20 2001-09-11 Isis Pharmaceuticals, Inc. Antisense inhibition of MEKK2 expression
US7182202B2 (en) 2005-05-31 2007-02-27 Franz Grimme Landmaschinenfabrik Gmbh & Co. Kg Conveying device for bulk material
US20070060526A1 (en) 2005-06-08 2007-03-15 Longo Frank M Methods of facilitating neural cell survival using non-peptide and peptide BDNF neurotrophin mimetics
US10867398B2 (en) 2017-11-21 2020-12-15 Reliance Core Consulting LLC Methods, systems, apparatuses and devices for facilitating motion analysis in an environment

Non-Patent Citations (49)

* Cited by examiner, † Cited by third party
Title
AIRAKSINEN; SAARMA: "The GDNF family: signalling, biological functions and therapeutic value", NAT REV NEUROSCI., vol. 3, 2002, pages 383 - 94
AIRAVAARA ET AL.: "Increased extracellular dopamine concentrations and FosB/DeltaFosB expression in striatal brain areas of heterozygous GDNF knockout mice", EUR J NEUROSCI., vol. 20, 2004, pages 2336 - 44
BALOH ET AL.: "Functional mapping of receptor specific city domains of glial cell line-derived neurotrophic factor (GDNF) family ligands and production of GFRal RET-specific agonists", J BIOL CHEM., vol. 275, 2000, pages 3412 - 20
BESPALOV; SAARMA: "GDNF family receptor complexes are emerging drug targets", TRENDS PHARMACOL SCI., vol. 28, 2007, pages 68 - 74
ENSLEN ET AL.: "Regulation of mitogen-activated protein kinases by a calcium/calmodulin-dependent protein kinase cascade", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 93, 1996, pages 10803
GARCES ET AL.: "Responsiveness to neurturin of subpopulations of embryonic rat spinal motoneuron does not correlate with expression of GFR a 1 or GFR a 2", DEV DYN., vol. 220, 2001, pages 189 - 97
GARDELL ET AL.: "Multiple actions of systemic artemin in experimental neuropathy", NAT MED., vol. 9, 2003, pages 1383 - 9
GILL ET AL.: "Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease", NAT MED., vol. 9, 2003, pages 589 - 95
GOLDEN ET AL.: "Neurturin and persephin promote the survival of embryonic basal forebrain cholinergic neurons in vitro", EXP NEUROL., vol. 184, 2003, pages 447 - 55
HE ET AL.: "Glial cell line-derived neurotrophic factor mediates the desirable actions of the anti-addiction drug ibogaine against alcohol consumption", J NEUROSCI., vol. 25, 2005, pages 619 - 28
HENDERSON ET AL.: "GDNF: a potent survival factor for motoneurons present in peripheral nerve and muscle", SCIENCE, vol. 266, 1994, pages 1062 - 4
KATRITZKY ET AL.: "Novel computational models for predicting dopamine interactions", EXPERIMENTAL NEUROLOGY, vol. 211, 2008, pages 150 - 171
KIRIK-D, EXP. NEUROL., vol. 152, 1998, pages 259 - 277
KNOWLES ET AL.: "Structure and chemical inhibition of the RET tyrosine kinase domain", J BIOL CHEM., vol. 281, 2006, pages 33577 - 87
LANG ET AL.: "Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease", ANN NEUROL., vol. 59, 2006, pages 459 - 66
LEPPANEN ET AL.: "The structure of GFRal domain 3 reveals new insights into GDNF binding and RET activation", EMBO J., vol. 23, 2004, pages 1452 - 62
LIN ET AL.: "GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons", SCIENCE, vol. 260, 1993, pages 1130 - 2
LINDHOLM ET AL.: "Novel neurotrophic factor CDNF protects and rescues midbrain dopamine neurons in vivo", NATURE, vol. 448, 2007, pages 73 - 7
MARAIS ET AL.: "The SRF accessory protein Elk- contains a growth factorregulated transcriptional activation domain", CELL, vol. 73, 1993, pages 381 - 93
MARKS ET AL.: "Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial", LANCET NEUROL., vol. 7, 2008, pages 400 - 8
MENG ET AL.: "Promotion of seminomatous tumors by targeted overexpression of glial cell line-derived neurotrophic factor in mouse testis", CANCER RES., vol. 61, 2001, pages 3267 - 71
MENG ET AL.: "Regulation of cell fate decision of undifferentiated spermatogonia by GDNF", SCIENCE, vol. 287, 2000, pages 1489 - 93
MESSER ET AL.: "Role for GDNF in biochemical and behavioral adaptations to drugs of abuse", NEURON., vol. 26, 2000, pages 247 - 57
MIJATOVIC ET AL.: "Constitutive Ret activity in knock-in multiple endocrine neoplasia type B mice induces profound elevation of brain dopamine concentration via enhanced synthesis and increases the number of TH-positive cells in the substantia nigra", J NEUROSCI., vol. 27, 2007, pages 4799 - 809
MOUTON ET AL., BRAIN RES., vol. 956, 2002, pages 30 - 35
PARDRIDGE ET AL., PHARMACOL. TOXICOL., vol. 71, 1992, pages 3 - 10
PARDRIDGE, TRENDS IN BIOTECHNOL., vol. 12, 1994, pages 239 - 245
PARKASH ET AL.: "The structure of the glial cell line-derived neurotrophic factorcoreceptor complex: insights into RET signaling and heparin binding", J BIOL CHEM., vol. 283, 2008, pages 35164 - 72
PAXINOS; WATSON: "The rat brain in stereotaxic coordinates", 1997, ACADEMIC PRESS
PICHEL ET AL.: "Defects in enteric innervation and kidney development in mice lacking GDNF", NATURE, vol. 382, 1996, pages 73 - 6
POLT ET AL., PROC. NATL. ACAD. SCI. USA, vol. 91, 1994, pages 7114 - 1778
RUNEBERG-ROOS ET AL.: "RET(MEN 2B) is active in the endoplasmic reticulum before reaching the cell surface", ONCOGENE, vol. 26, 2007, pages 7909 - 7915
S. M. BERGE ET AL.: "pharmaceutically acceptable salts in detail", J. PHARMACEUTICAL SCIENCES, vol. 66, 1977, pages 1 - 19
SANTORO ET AL.: "Minireview: RET: normal and abnormal functions", ENDOCRINOLOGY, vol. 145, 2004, pages 5448 - 51
SARIOLA; SAARMA: "Novel functions and signalling pathways for GDNF", J CELL SCI., vol. 116, 2003, pages 3855 - 62
SAUER H; OERTEL WH: "Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-hydroxydopamine: a combined retrograde tracing and immunocytochemical study in the rat", NEUROSCIENCE, vol. 59, no. 2, 1994, pages 401 - 15
SAUTTER ET AL.: "Implants of polymer-encapsulated genetically modified cells releasing glial cell line-derived neurotrophic factor improve survival, growth, and function of fetal dopaminergic grafts", EXP NEUROL., vol. 149, 1998, pages 230 - 6
SCHINELLI S; ZUDDAS A; KOPIN IJ; BARKER JL; DI PORZIO U: "1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine metabolism and 1-methyl-4-phenylpyridinium uptake in dissociated cell cultures from the embryonic mesencephalon", J NEUROCHEM, vol. 50, no. 6, 1988, pages 1900 - 7
SHASHOUA ET AL., J. MED. CHEM., vol. 27, 1984, pages 659 - 664
SILD ET AL.: "Open computing grid for molecular science and engineering", J CHEM INF MODEL., vol. 46, 2006, pages 953 - 9
SLEVIN ET AL.: "Improvement of bilateral motor functions in patients with Parkinson disease through the unilateral intraputaminal infusion of glial cell line-derived neurotrophic factor", J NEUROSURG., vol. 102, 2005, pages 216 - 22
TOKUGAWA ET AL.: "XIB4035, a novel nonpeptidyl small molecule agonist for GFRa-1", NEUROCHEM INT., vol. 42, 2003, pages 81 - 6
TOMAC ET AL.: "Effects of cerebral ischemia in mice defi cient in Persephin", PROC NATL ACAD SCI U S A., vol. 99, 2002, pages 9521 - 6
TOTH ET AL., J. DRUG TARGET., vol. 2, 1994, pages 217 - 239
TOVAR ET AL.: "Comparison of 2D Fingerprint Methods for Multiple-Template Similarity Searching on Compound Activity Classes of Increasing Structural Diversity", CHEMMEDCHEM., vol. 2, 2007, pages 208 - 217
VAN BREE ET AL., PHARM. WORLD SCI., vol. 15, 1993, pages 2 - 9
WANG ET AL.: "Persistent restoration of sensory function by immediate or delayed systemic artemin after dorsal root injury", NAT NEUROSCI., vol. 11, 2008, pages 488 - 96
WANG ET AL.: "Structure of artemin complexed with its receptor GFRa3: convergent recognition of glial cell line-derived neurotrophic factors", STRUCTURE, vol. 14, 2006, pages 1083 - 92
WEST ET AL., ANAT. REC., vol. 231, 1991, pages 482 - 497

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014041179A1 (fr) * 2012-09-17 2014-03-20 Chemedest Ltd. Traitement d'une neuropathie périphérique à l'aide d'agonistes du récepteur de type 3 de gfr(alpha)3
US20160136159A1 (en) * 2012-09-17 2016-05-19 Chemedest Ltd. Method for Treating Peripheral Neuropathy
US20180036305A1 (en) * 2012-09-17 2018-02-08 Chemedest Ltd. Method of treating peripheral neuropathy
CN103146798A (zh) * 2013-02-25 2013-06-12 潍坊易思特生物科技有限公司 一种测定重组人胶质细胞源性神经营养因子活性的细胞学方法
CN105640955A (zh) * 2016-01-28 2016-06-08 昆明医科大学 一种Aminoquinol的新用途
CN105640955B (zh) * 2016-01-28 2019-12-24 昆明医科大学 一种Aminoquinol的新用途
WO2017195042A1 (fr) 2016-05-13 2017-11-16 Instituto De Medicina Molecular Méthodes de traitement de maladies associées à des cellules ilc3
WO2022207846A1 (fr) 2021-03-31 2022-10-06 Cambridge Enterprise Limited Inhibiteurs thérapeutiques de la signalisation gdf15
WO2022254255A1 (fr) 2021-06-03 2022-12-08 Fundacao D. Anna De Sommerchampalimaud E Dr. Unités neuro-mésenchymes de lutte contre l'ilc2 et l'obésité par l'intermédiaire d'un circuit du cerveau-adipeux
WO2024023287A1 (fr) * 2022-07-28 2024-02-01 Genecode Dérivés de [4-[5-(méthylsulfonyl)-phényl]pipérazin-1-yl]-(phényl)méthanone et composés similaires ayant une activité gfr alpha 1-ret utilisés en tant qu'agents neuroprotecteurs pour le traitement de troubles neurologiques
WO2024023284A1 (fr) 2022-07-28 2024-02-01 Genecode Nouveaux sulfonamides et leur utilisation en tant qu'agents neuroprotecteurs et/ou neurorestorateurs
WO2024079351A1 (fr) 2022-10-14 2024-04-18 Genecode Nouveaux sulfonamides à base de pipérazine et leur utilisation comme agents neuroprotecteurs et/ou neurorestorateurs

Also Published As

Publication number Publication date
JP2013513588A (ja) 2013-04-22
US8901129B2 (en) 2014-12-02
EP2509953A2 (fr) 2012-10-17
CA2783934A1 (fr) 2011-06-16
EP2509953B1 (fr) 2016-03-30
WO2011070177A3 (fr) 2011-09-01
BR112012014022A2 (pt) 2017-04-04
MX2012006580A (es) 2012-09-28
CN104529945A (zh) 2015-04-22
CN103180297A (zh) 2013-06-26
US20130030180A1 (en) 2013-01-31
AU2010329847A1 (en) 2012-07-26

Similar Documents

Publication Publication Date Title
EP2509953B1 (fr) Procédés destinés à faciliter la survie de cellules neuronales en utilisant des mimétiques de ligands de la famille des gdnf (gfl) ou des activateurs de la voie de signalisation du ret
Zhang et al. Modulation of brain cation-Cl− cotransport via the SPAK kinase inhibitor ZT-1a
KR102123365B1 (ko) 항박테리아 치료제 및 예방제
US20090156611A1 (en) Mammalian hedgehog signaling modulators
US6235769B1 (en) Methods of preventing and treating neurological disorders with compounds that modulate the function of the C-RET receptor protein tyrosine kinase
US7053116B2 (en) Methods for protecting cells from amyloid toxicity and for inhibiting amyloid protein production
KR101939401B1 (ko) 단핵식세포계 세포의 ａｇｅ-알부민 합성 또는 분비 저해제를 유효성분으로 포함하는 허혈성 심장질환 예방 또는 치료용 조성물
KR20180073553A (ko) 알데히드 접합체 및 이의 용도
KR20100024951A (ko) 세포를 자극하기 위한 방법 및 조성물
RU2654910C2 (ru) Производные бензилиденгуанидина и их терапевтическое применение для лечения заболеваний, связанных с неправильным сворачиванием белков
EP1917017B1 (fr) Traitement de la sclerose amyotrophique laterale avec la pyrimethamine et des analogues
US20020045566A1 (en) Selective maxi-K potassium channel openers functional under conditions of high intracellular calcium concentration, methods and uses thereof
US10022357B2 (en) Amyloid precursor protein MRNA blockers for treating Down syndrome and Alzheimer's disease
JP2019501225A (ja) Ｂ細胞リンパ腫２（ｂｃｌ−２）及び関連タンパク質の阻害
WO2018053373A1 (fr) Utilisations d'inhibiteurs de kinase inductible par un sel (sik) pour traiter l'ostéoporose
CA3214155A1 (fr) Procedes d'inhibition de ras
Yan et al. Activation of large-conductance Ca2+-activated K+ channels inhibits glutamate-induced oxidative stress through attenuating ER stress and mitochondrial dysfunction
Xie et al. A dual role of ATM in ischemic preconditioning and ischemic injury
US20210113600A1 (en) Restoring physiology with small molecule mimics of missing proteins
EP1278537B1 (fr) Compositions de stimulation de la regeneration et de la reparation du systeme nerveux par regulation de l'activite de l'arginase 1 et de la synthese des polyamines
US20170172987A1 (en) Isoxazole treatments for frontotemporal dementia
AU2013291970B2 (en) Baclofen and acamprosate based therapy of Macular Degeneration disorders
JP2008500368A (ja) 細胞保護のための２置換１７−イミノエストロゲン化合物
JP2000500490A (ja) 糖尿病治療用の４−ヒドロキシクマリン−３−カルボキシアミド
US20220041667A1 (en) Targeting of makap-pde4d3 complexes in neurodegenerative disease

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10790954

Country of ref document: EP

Kind code of ref document: A1

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10790954

Country of ref document: EP

Kind code of ref document: A1

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
ENP Entry into the national phase

Ref document number: 2783934

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: MX/A/2012/006580

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2012542580

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2010329847

Country of ref document: AU

Ref document number: 5712/CHENP/2012

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2010790954

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2010329847

Country of ref document: AU

Date of ref document: 20101213

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 13514906

Country of ref document: US

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112012014022

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112012014022

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20120611